Previous 10 | Next 10 |
– Combined Company Will Operate as Biosight Therapeutics to Advance Pipeline of Clinical-Stage Oncology Programs with Lead Program Aspacytarabine (BST-236) in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) – Combined Company Will be Well-Fu...
ADXS-503 Phase 1/2 trial data presented at ASCO demonstrate disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on KEYTRUDA ® Expansion of off-the-shelf ADXS-HOT program with planned Phase 1 study in ea...
Penny Stocks To Buy On Robinhood, Webull, Fidelity & Others To Watch This Week Penny stocks are some of the most volatile asset classes in the stock market today. But thanks to the growing interest in things like crypto and options, retail traders have pushed risk aside in exchange ...
4 Biotech Penny Stocks to Watch Right Now As you put together a penny stock watchlist for the month of June you might want to keep in mind what news could come out during the month. The biotech industry is well-known for releasing news often. This can occur prior to a new compounds roll...
Best Penny Stocks to Buy Under $2? Check These 3 Out Penny stocks and the entire stock market are making big moves today. This comes only a day after a very disappointing trading session. And if it seems confusing, it’s worth noting that this is the normal trajectory that penny...
Advaxis (ADXS) released updated data from an ongoing Phase 1/2 trial for its off-the-shelf immunotherapy ADXS-503 in combination with Merck’s KEYTRUDA (pembrolizumab) in patients with metastatic non-small-cell lung cancer ((NSCLC)).The results will be part of a poster present...
Updated data show disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on pembrolizumab Translational data support potential of ADXS-503 to restore and/or enhance sensitivity to checkpoint inhibitors PRINCE...
Gainers: MoSys (MOSY) +32%.Lianluo Smart (LLIT) +30%.Advaxis (ADXS) +27%.Reata Pharmaceuticals (RETA) +22%.LifeMD (LFMD) +18%.Taitron Components (TAIT) +17%.FreightCar America (RAIL) +14%.Transcat (TRNS) +14%.PureCycle Technologies (PCT) +14%.Aehr Test Systems (AEHR) +12%.Losers:...
Top Biotech Penny Stocks to Watch Right Now With Bitcoin Price Dipping Below $40,000 While most penny stocks and blue chips are having a rough day, there are always some big gainers to look at. With penny stocks , we often see steep rises even when overall markets are down. And this...
PRINCETON, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that will present data from Part B of the Phase 1 study of ADXS-503 in co...
News, Short Squeeze, Breakout and More Instantly...
MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the “SEC”) to deregister its common stock under Section 12(g) ...
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM). As per the ...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 ...